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Recently within 2 days of each other, two of the leading medi-
cal journals published trials on the use of prehospital fresh frozen 
plasma (FFP) for trauma patients, reaching apparently different 
conclusions. In the New England Journal of Medicine article reporting 
on the Prehospita旭 Air Medica旭 P旭asma ｪPAMPerｫ tria旭p Sperry et a旭1 
found that two units of prehospital FFP was associated with an al-
most ゲグ鯵 surviva旭 advantages In the Contro旭 of Major B旭eeding After 
Trauma Tria旭 ｪCOMBATｫ reported in the Lancetp Moore et a旭2 found 
that the same volume of plasma had no survival advantage.
The concept of prehospital plasma is in theory attractive. You 
have an injured individual who is likely to need plasma in the next 
few hours, so why not preemptively reduce the bleeding by adminis-
tering p旭asma firstn An important issue to considerp howeverp is that 
at the injury scene the patient is not likely to be deficient in clotting 
factors yet. The prehospital transfusion of blood products has been 
shown to improve survival in US military combat casualties injured 
in Afghanistans3
The normal range for clotting factors measured as percent of 
normal is approximately 50- 150 with a mean of 100. It follows, that 
the average individual can lose half their plasma volume and still 
have clotting factor levels in the normal range even after reconstitu-
tion of b旭ood vo旭umes A major reduction in c旭otting factors can occur 
in two relevant settings, firstly when there is marked hemodilution 
such as that following major fluid resuscitation and secondly due to 
consumption in the presence of disseminated intravascular coagula-
tion (DIC). With the exception of obstetric DIC at the time of deliv-
ery, this consumption is not usually so rapid to become a major issue 
in the prehospital management of trauma.
Fresh frozen plasma is obtained from whole blood donation or 
p旭asmapheresiss Whi旭e in the COMBAT tria旭 they specify that they 
gave two units of approximate旭y ゴズグ mL each of FFPp the PAMPer 
investigators do not specify the volume of the two units they 
administereds The PAMPer FFP was prethawed and cou旭d be up to 
ズ days since thawingp whi旭e the COMBAT product was co旭旭ected by 
plasmapheresis, frozen within 24 hours and thawed rapidly in special 
equipment before administration. In a study one of us was involved 
in, measuring clotting factor levels before and after administration of 
four units of optimally thawed FFP just before infusion, the increase 
in clotting factor levels was 9%- 14%.4 Based on the volume of FFP 
infused in the PAMPer and COMBAT studiesp the increase in fac-
tor levels would be 7% at best. This suggests that if prehospital FFP 
provides benefit, it is unlikely that this is through the substitution of 
coagulation factors. Other modes of FFP benefit include protecting 
the endothelial glycocalyx and reducing vascular permeability and 
inflammation.5,6
We compared the PAMPer and COMBAT tria旭s 旭ooking for dif-
ferences in their design and conduct to shed light on the true ef-
fect of FFP, if any (Table 1). Of course, the simplest explanation for 
the difference in results could well be a combination of chance and 
旭ow power for the COMBAT studyp due to 旭ow event rate and sma旭旭 
samp旭e sizes The contribution of the COMBAT tria旭 under a fixed ef-
fect meta- analysis approach would have been <10%, and the pooled 
estimatesp driven by the 旭arger PAMPer studyp wou旭d have shown 
a significant benefit for plasma administration at both 24 hours 
(OR = 0.64, 95% CI 0.42- 0.98) and 1 month (OR = 0.67, 95% CI 0.46- 
0.98). Even under the more conservative random- effect approach, 
the visual inspection of the forest plot (Figure 1) would support both 
the hypothesis the two trials observing a different effect (as their 
effect sizes lie on opposite sides of the identity line) and instead 
representing random variation of the same effect (as the confidence 
intervals do overlap). However, there are clear differences between 
the trials, starting from the choice of results to report and the modal-
ity used to report them. The entry criteria for the two trials were the 
same in terms of blood pressure and heart rate measurements, but 
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TABLE  ゲ科Comparison of the PAMPer and COMBAT tria旭s
PAMPer tria旭 COMBAT tria旭
FFP Standard care FFP Saline
Patient characteristics
Number 230 271 65 60
Age median ｪyｫ 44 46 33 32.5
Male (%) 71.3 73.8 80 85
Blunt injury 81.3 83.4 46 53
Prothrombin time ratio or INR on 
arrival at hospital
1.2 1.3 1.27 1.15
Injury severity
Prehospital intubation (%) 50 52 Not given
Prehospital red cells (%) 26.1 42.1 Not given
Transfused red cells in first 24 h (%) Not given 55 58
Injury severity score (median) 22 21 27
Operations in first 24 h (%) 71.7 80.1 Not given
Setting US air medical transport Denver, US ground transport
Median prehospital transfer time 
(min)
42 40 19 16
Entry qualification BP <90 mm Hg plus pulse >108 or BP <70 BP <90 mm Hg plus pulse >108 or BP <70
Randomization Cluster randomization to plasma or standard 
care at monthly intervals. Treating staff not 
blinded.
Individual randomization by the content of coolers. 
Treating staff not blinded
Intervention 2 units pre- thawed 
up to 5- day- old 
plasma
Standard care no fluid 
volume stipulated
2 units apheresis 
FFP approx 
ズググ mL
Norma旭 sa旭ine as per standard 
care (volume not same)
Prehospita旭 crysta旭旭oid ｪmLｫ 500 900 150 250
Outcome
24- h mortality (%) 13.9 22.1 12 10
28- or 30- day mortality (%) 23.2 33 15 10
COMBATp Contro旭 of Major B旭eeding After Trauma Tria旭q FFPp fresh frozen p旭asmaq PAMPerp Prehospita旭 Air Medica旭 P旭asmas
F IGURE  ゲ科Random effect meta､ ana旭ysis of morta旭ity data from the PAMPer and COMBAT tria旭ss CIp confidence interva旭q COMBATp 
Contro旭 of Major B旭eeding After Trauma Tria旭q PAMPerp Prehospita旭 Air Medica旭 P旭asma tria旭
Study or subgroup Events Total Events Total Weight M-H, random, 95% CI M-H, random, 95% CI
Odds ratioPre-hospital FFP Standard of care Odds ratio
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the PAMPer tria旭 patients were o旭derp more 旭ike旭y fema旭e and much 
more likely to have sustained a blunt injury. In terms of severity of 
the injuryp as defined by the injury severity scorep the COMBAT tria旭 
patients were more severely affectedunfortunately, we do not 
have the data on prehospital intubation and interventions in the first 
ゴジ hours for the COMBAT tria旭s
An important difference between the tria旭s emerges on 旭ooking 
at the control arms, both receiving standard care. These individuals 
had identical entry criteria and in theory similar management plans 
after reaching the hospital facility. However, the 24- hour mortality 
was ゲグ鯵 in the COMBAT tria旭 and ゴゴ鯵 in PAMPerp whi旭e the respec-
tive 28- to 30- day mortality was 10% and 33%. Such large differ-
ences must relate to differences in severity of the injury in the two 
groups, which unfortunately is not reported with sufficient details to 
a旭旭ow a direct comparisons As these data must have been co旭旭ectedp 
the authors should be encouraged to publish data allowing direct 
comparison between the two trials, especially detailing the injury 
severity. It would also be good to see retrospective data from both 
research networks showing whether the mortality figures observed 
in the two trials are representative of their previous experience or 
they happened to se旭ect a more ｪPAMPerｫ or 旭ess ｪCOMBATｫ severe 
population.
Since both trials were randomized, one would expect the two 
arms to be comparable in every aspect except for the intervention. 
In the PAMPer tria旭p howeverp ジゴs葦鯵 of the standard care patients 
received prehospital red cells (vs 26.1% in the FFP arm) and an aver-
age ジググ mL more crysta旭旭oid before reaching hospita旭s Both of these 
features could contribute to the higher mortality in the standard 
care group of the PAMPer studys
The transfer times from the scene of injury to hospital were longer 
at ジグ､ ジゴ minutes when performed by he旭icopter ｪPAMPerｫ whi旭e on旭y 
ゲ葦､ ゲゾ minutes by road ambu旭ance ｪCOMBATｫs It can be argued that for 
road transfers, the interval is so short that it is unlikely that any prehos-
pital intervention will make much difference, and intervention driven 
differences would be more likely seen as the transfer time increases.
Irrespective of all the above issues, we believe the two studies 
show that if there is a benefit for prehospital FFP, this is not due to 
the clotting factors in the product. The coagulopathy of the patients 
in both trials on arrival to hospital was very mild, with a median pro-
thrombin time ratio or INR of ゲsザ or 旭esss Furthermore the COMBAT 
trial investigators report that the median levels for fibrinogen and 
factors II, V, VII, IX, XI, and XIII on arrival to hospital were normal in 
both groups and indeed were higher in the non- FFP group.
No adverse events in re旭ation to the administration of the FFP 
were observed but three important issues need to be considered 
before implementing prehospital FFP as a policy: 
ｪAｫ   The FFP used was a not vira旭旭y inactivated b旭ood product and can 
in theory transmit infections. This can be due to the donors being 
viremic shortly after infection (before the development of anti-
bodies), due to currently unknown infections, or due to prions.
(B)  The delay in getting the injured individual to hospital whist try-
ing to thaw and administer the FFP outside a clinical trial setting.
(C)  The fact that if all emergency ambulances and helicopters carry 
thawed universa旭 donor b旭ood group AB p旭asmap the a旭ready 
known frequent shortages of this product will be exacerbated. 
Lyophi旭ized FFP may overcome this 旭imitation in the future but it 
is not currently routinely available.7
Our conclusion reflecting on these two randomized clinical trials is 
that the case for universal use of prehospital FFP is not yet made. Until 
further results from these trials are published to guide interpretation 
of current evidence and planning of future large pragmatic trials, it 
would be better for first response teams to concentrate on getting 
the injured individual to the controlled hospital environment as soon 
as possible, rather than investing precious time in administering FFP 
before transfer. Indeed, even assuming plasma can benefit a subgroup 
of more severely injured patients, it might be difficult to stratify them 
with the little time and few tools available at the injury site.
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